188 related articles for article (PubMed ID: 38580362)
1. Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis.
Zhang C; Chen X; Wang J; Luo T
BMJ Open; 2024 Apr; 14(4):e070364. PubMed ID: 38580362
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Efficacy of Contrast-Enhanced MRI in Detecting Residual or Recurrent Hepatocellular Carcinoma After Transarterial Chemoembolization: A Systematic Review and Meta-analysis.
Liu HF; Zou LQ; Lu XR; Sheng Y; Wang Q; Ding JL; Shi L; Liu SQ; Xing W
J Magn Reson Imaging; 2020 Oct; 52(4):1019-1028. PubMed ID: 31675170
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
[TBL] [Abstract][Full Text] [Related]
4. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis.
Zhong J; Su Z; Zhang Y; Zhang H; Lin P; Tang X; Zheng R
J Ultrasound Med; 2018 Aug; 37(8):1881-1890. PubMed ID: 29380404
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis value of focal liver lesions with SonoVue®-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis.
Guang Y; Xie L; Ding H; Cai A; Huang Y
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1595-605. PubMed ID: 21850382
[TBL] [Abstract][Full Text] [Related]
6. On-Site Diagnostic Ability of CEUS/CT/MRI for Hepatocellular Carcinoma (2019-2022): A Multicenter Study.
Yang Q; Zheng R; Zhou J; Tang L; Zhang R; Jiang T; Jing X; Liao J; Cheng W; Zhao C; Liu C; Dietrich CF; Cui X; Cai W; Wu J; Yu F; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
J Ultrasound Med; 2023 Dec; 42(12):2825-2838. PubMed ID: 37713625
[TBL] [Abstract][Full Text] [Related]
7. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
[TBL] [Abstract][Full Text] [Related]
8. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.
Lu MD; Yu XL; Li AH; Jiang TA; Chen MH; Zhao BZ; Zhou XD; Wang JR
Ultrasound Med Biol; 2007 Nov; 33(11):1736-49. PubMed ID: 17629608
[TBL] [Abstract][Full Text] [Related]
9. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
10. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
11. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.
Bo J; Peng H; LianHua Z; Xiang F; YuKun L
BMC Cancer; 2021 Nov; 21(1):1171. PubMed ID: 34727882
[TBL] [Abstract][Full Text] [Related]
12. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.
Bo XW; Xu HX; Wang D; Guo LH; Sun LP; Li XL; Zhao CK; He YP; Liu BJ; Li DD; Zhang K
Br J Radiol; 2016 Nov; 89(1067):20160379. PubMed ID: 27626506
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced ultrasound and contrast-enhanced computed tomography for differentiating mass-forming pancreatitis from pancreatic ductal adenocarcinoma: a meta-analysis.
Yang J; Huang J; Zhang Y; Zeng K; Liao M; Jiang Z; Bao W; Lu Q
Chin Med J (Engl); 2023 Sep; 136(17):2028-2036. PubMed ID: 36728948
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis.
Xie L; Guang Y; Ding H; Cai A; Huang Y
Ultrasound Med Biol; 2011 Jun; 37(6):854-61. PubMed ID: 21531500
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.
Jhaveri KS; Babaei Jandaghi A; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G
Cancer Imaging; 2023 Feb; 23(1):22. PubMed ID: 36841796
[TBL] [Abstract][Full Text] [Related]
17. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
[TBL] [Abstract][Full Text] [Related]
19. Is Gadoxetic Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging an Accurate Diagnostic Method for Hepatocellular Carcinoma? A Systematic Review with Meta-Analysis.
Yinzhong W; Xiaoxue T; Jinhui T; Pengcheng Y; Xiaoying L; Junqiang L
Curr Med Imaging; 2022; 18(6):633-647. PubMed ID: 34533447
[TBL] [Abstract][Full Text] [Related]
20. Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis.
Liu Z; Fan JM; He C; Li ZF; Xu YS; Li Z; Liu HF; Lei JQ
Cancer Imaging; 2020 Jan; 20(1):3. PubMed ID: 31907050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
